D-galactosyl--1,1' N-lauroyl-D-erythro-sphingosine

C12 Galactosylceramide is a bioactive sphingolipid. It inhibits IL-4 production by 53.84% in EL4 T cells when used at a concentration of 10 μM. C12 Galactosylceramide reduces the growth of human papillomavirus type 16-associated tumors in mice and reduces tumor recurrence following surgical removal or chemotherapy. It also reduces natural killer T cell activity, delays the onset of proteinuria, and improves survival in a mouse model of systemic lupus. [Matreya, LLC. Catalog No. 1937]

Dodecanoyl-galactosylceramide is an ester product.

ChEBI: Beta-D-galactosyl-N-(dodecanoyl)sphingosine is a D-galactosyl-N-acylsphingosine in which the ceramide N-acyl group is dodecanoyl.

[1] JIN PARK . Inhibitory activity of a ceramide library on interleukin-4 production from activated T cells[J]. Bioorganic & Medicinal Chemistry, 2005, 13 7: Pages 2589-2595. DOI: 10.1016/j.bmc.2005.01.027
[2] JANA íMOVá. Therapy for minimal residual tumor disease: β-Galactosylceramide inhibits the growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy[J]. International Journal of Cancer, 2010, 126 12: 2997-3004. DOI: 10.1002/ijc.24887
[3] SUFI R. MORSHED . β-galactosylceramide alters invariant natural killer T cell function and is effective treatment for lupus[J]. Clinical immunology, 2009, 132 3: Pages 321-333. DOI: 10.1016/j.clim.2009.05.018